Status:
COMPLETED
A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)
Lead Sponsor:
Merck Sharp & Dohme LLC
Collaborating Sponsors:
Celerion
Conditions:
Healthy
Eligibility:
All Genders
19-55 years
Phase:
PHASE1
Brief Summary
Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood. Enlicitide decanoate wil...
Eligibility Criteria
Inclusion
- The key inclusion criteria include but are not limited to the following:
- Is in good health before randomization
- Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive
Exclusion
- The key exclusion criteria include but are not limited to the following:
- Has a history of clinically significant psychiatric, immunological, gastrointestinal, cardiovascular abnormalities or diseases.
- Has a history of cancer.
- Has positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) at the screening visit.
Key Trial Info
Start Date :
October 7 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 15 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06597760
Start Date
October 7 2024
End Date
November 15 2024
Last Update
November 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Celerion ( Site 0001)
Lincoln, Nebraska, United States, 68502